MMM

3M Company (3M CO) - Q2 2002 10-Q Summary

Business Context and Reporting Period

This filing covers the quarterly period ended June 30, 2002. 3M Company, incorporated in Delaware, operates globally in more than 60 countries, deriving over half of its revenues from outside the United States. The company manufactures a diverse portfolio of products across six business segments: Transportation, Graphics and Safety; Health Care; Industrial; Consumer and Office; Electro and Communications; and Specialty Material.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Q2 2002 sales increased 2.1% year-over-year, driven by a 0.6% volume increase and 0.7% price increase. Currency translation added 0.8% to sales. However, for the six-month period, sales declined 2.3% due to a stronger U.S. dollar and lower core volumes.
• Profitability Surge: Net income more than doubled in Q2 2002 compared to Q2 2001. This is largely attributable to significantly lower restructuring charges in 2002 ($148 million) compared to 2001 ($397 million) and the cessation of goodwill amortization due to the adoption of SFAS No. 142.
• Cost Management: Cost of sales as a percentage of sales decreased to 51.5% in Q2 2002 from 55.6% in Q2 2001. SG&A expenses dropped to 22.1% of sales from 29.2% in the prior year, aided by employment reductions and the elimination of goodwill amortization.
• Balance Sheet: Total debt decreased by $249 million from year-end 2001. Working capital increased by $650 million to $2.437 billion, primarily due to a shift of debt from short-term to long-term.

Guidance, Outlook, and Risks

• 2002 Earnings Guidance: Management expects full-year 2002 reported earnings to be between $4.88 and $5.03 per diluted share. Excluding non-recurring items, the range is $5.15 to $5.30 per diluted share.
• Q3 2002 Outlook: Earnings are expected to be between $1.35 and $1.40 per diluted share.
• Restructuring Plan: The company expects to eliminate approximately 6,700 positions in total under the current plan. No additional charges are expected for the remainder of 2002, though cash payments of approximately $100 million are anticipated. The plan is projected to generate approximately $500 million in annualized savings upon completion.
• Key Risks:
  • Currency Fluctuations: A strengthening U.S. dollar negatively impacts international sales and earnings translation.
  • Legal Proceedings: Significant exposure remains regarding breast implant litigation (95 lawsuits, 607 claimants) and respirator/mask/asbestos litigation (approx. 74,700 claimants). While the company believes liabilities are adequately reserved, adverse rulings could occur.
  • Economic Conditions: Continued global economic weakness, particularly in the U.S. and Europe, impacts volume growth.
• Accounting Changes: The adoption of SFAS No. 142 (Goodwill) and SFAS No. 144 (Discontinued Operations) effective Jan 1, 2002, eliminated goodwill amortization, boosting earnings by approximately 4 cents per share in Q2 2002.

Investor Verification Checklist

• Verify the sustainability of the 21.4% increase in pro forma earnings per share, distinguishing between operational improvements and the one-time benefit of ceased goodwill amortization.
• Monitor the status of the breast implant and asbestos/respirator litigation, specifically the outcome of the Minnesota Court of Appeals decision expected in Q3 2002 regarding insurance coverage.
• Assess the impact of the U.S. dollar strength on international sales volumes and margins, as currency headwinds reduced earnings by 3 cents per share in Q2.
• Review the progress of the restructuring plan to ensure the projected $500 million in annualized savings materializes without further unexpected charges.
• Confirm the company's ability to maintain the 32.5% effective tax rate as projected for the remainder of the year.